- Home
- WHWK vs STRO Comparison
WHWK vs STRO Comparison
Compare WHWK & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | STRO |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 85.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | WHWK | STRO |
|---|---|---|
| Price | $2.61 | $9.92 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 168.6K | 121.9K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,384,000.00 | ★ $105,646,000.00 |
| Revenue This Year | N/A | $62.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $5.23 |
| 52 Week High | $3.81 | $21.50 |
Technical Indicators
Market Signals| Indicator | WHWK | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 78.91 |
| Support Level | $2.30 | $9.53 |
| Resistance Level | $2.63 | $10.10 |
| Average True Range (ATR) | 0.16 | 0.93 |
| MACD | 0.00 | 0.15 |
| Stochastic Oscillator | 74.47 | 98.52 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.